212 related articles for article (PubMed ID: 19702555)
1. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.
Guiard BP; El Mansari M; Blier P
Curr Drug Targets; 2009 Nov; 10(11):1069-84. PubMed ID: 19702555
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons.
Guiard BP; Chenu F; El Mansari M; Blier P
Int J Neuropsychopharmacol; 2011 Mar; 14(2):211-23. PubMed ID: 20149268
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
[TBL] [Abstract][Full Text] [Related]
4. [Consequences of the monoaminergic systems cross-talk in the antidepressant activity].
Tritschler L; Gaillard R; Gardier AM; David DJ; Guilloux JP
Encephale; 2018 Jun; 44(3):264-273. PubMed ID: 29801770
[TBL] [Abstract][Full Text] [Related]
5. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
Shaw AM; Boules M; Zhang Y; Williams K; Robinson J; Carlier PR; Richelson E
Eur J Pharmacol; 2007 Jan; 555(1):30-6. PubMed ID: 17109850
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
8. The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Li XR; Tang Y; Xiong J; Chen HX; Xue R; Li YF
Eur Neuropsychopharmacol; 2015 Apr; 25(4):544-56. PubMed ID: 25638027
[TBL] [Abstract][Full Text] [Related]
9. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions.
Guiard BP; El Mansari M; Merali Z; Blier P
Int J Neuropsychopharmacol; 2008 Aug; 11(5):625-39. PubMed ID: 18205979
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiology and Behavioral Assessment of the New Molecule SMe1EC2M3 as a Representative of the Future Class of Triple Reuptake Inhibitors.
Koprdova R; Csatlosova K; Durisova B; Bogi E; Majekova M; Dremencov E; Mach M
Molecules; 2019 Nov; 24(23):. PubMed ID: 31757051
[TBL] [Abstract][Full Text] [Related]
11. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus.
Guiard BP; El Mansari M; Blier P
Mol Pharmacol; 2008 Nov; 74(5):1463-75. PubMed ID: 18703671
[TBL] [Abstract][Full Text] [Related]
13. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats.
Zhang R; Li X; Shi Y; Shao Y; Sun K; Wang A; Sun F; Liu W; Wang D; Jin J; Li Y
PLoS One; 2014; 9(3):e91775. PubMed ID: 24614602
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons.
Katz NS; Guiard BP; El Mansari M; Blier P
J Psychopharmacol; 2010 Aug; 24(8):1223-35. PubMed ID: 19939862
[TBL] [Abstract][Full Text] [Related]
15. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
Prins J; Olivier B; Korte SM
Expert Opin Investig Drugs; 2011 Aug; 20(8):1107-30. PubMed ID: 21682663
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
Skolnick P; Krieter P; Tizzano J; Basile A; Popik P; Czobor P; Lippa A
CNS Drug Rev; 2006; 12(2):123-34. PubMed ID: 16958986
[TBL] [Abstract][Full Text] [Related]
17. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.
Quesseveur G; Gardier AM; Guiard BP
Curr Drug Targets; 2013 Oct; 14(11):1277-94. PubMed ID: 24020973
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
Carlier PR; Lo MM; Lo PC; Richelson E; Tatsumi M; Reynolds IJ; Sharma TA
Bioorg Med Chem Lett; 1998 Mar; 8(5):487-92. PubMed ID: 9871604
[TBL] [Abstract][Full Text] [Related]
19. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
20. "Broad spectrum" antidepressants: is more better for the treatment of depression?
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Life Sci; 2003 Nov; 73(25):3175-9. PubMed ID: 14561522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
